XRLX yields 2.83% · PFE yields 6.13%● Live data
📍 PFE pulled ahead of the other in Year 9
Combined, XRLX + PFE cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of XRLX + PFE for your $10,000?
XRLX is a fund-of-funds that aims to capture global market trends. The adviser pursues a balanced approach by investing in core equity, total return, and bond underlying funds it considers to be in sync with current market leaders. The core equity funds allow participation in broad stock market leadership trends through diversified exposure to stocks of any size or style from around the world. Whereas the total return and bond underlying funds intend to reduce the risk and potential volatility of the core equity funds. The total return funds may utilize different investment strategies designed to provide steady income and low volatility. The underlying bond funds invest in US and non-US fixed income securities of any maturity and credit quality. As an actively managed fund, the adviser has full discretion to adjust portfolio positions towards more attractive investments. On October 9, 2023, XRLX converted from a mutual fund to an ETF structure, starting with $58.2 million in assets.
Full XRLX Calculator →Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
Full PFE Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.